



September 27, 2017

## Oxford Immunotec Announces Update in Patent Infringement Litigation

OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision of the U.S. District Court for the District of Massachusetts in the Company's patent infringement lawsuit against Qiagen, Inc., Quest Diagnostics, Inc. and Laboratory Corporation of America Holdings on the Company's motion seeking to enjoin Qiagen from promoting its QuantiFERON-TB Gold Plus (QFT-Plus) product to new customers in the U.S. Although the court denied the Company's motion because it believed the Company was not likely to suffer irreparable harm from QFT-Plus during the few months remaining before trial, it found that the Company was likely to prevail on the merits of its claims at trial and that Qiagen had not shown that it was likely to succeed on its subject matter, prior art or non-infringement objections. The court further noted that if the Company "prevails at trial, it is likely that the infringing aspects of the QFT Plus will be permanently enjoined."

"While we are disappointed that the court did not grant a preliminary injunction prohibiting the sale of Qiagen's QFT-Plus product in the U.S. before trial, we are encouraged by the court's rulings on the issues of validity and obviousness," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "We continue to look forward to the further defense of our patents at the upcoming trial in January."

### About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT<sup>®</sup>.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Also obtained through the acquisitions is the Company's third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure. The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the Company's fourth intended product line focused on the transplantation market. In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at [www.oxfordimmunotec.com](http://www.oxfordimmunotec.com).

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.

### CONTACT:

#### For Media and Investor Inquiries:

Karen Koski  
Head of Strategy and Investor Relations  
Oxford Immunotec  
Tel: +1 (508) 556-1377  
[kkoski@oxfordimmunotec.com](mailto:kkoski@oxfordimmunotec.com)